Valve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve replacement: A systematic review and meta-analysis.
Adham AhmedKenneth H LevyPublished in: Journal of cardiac surgery (2021)
Despite having patients with an increased baseline risk, ViV TAVR was associated with lower 30-day mortality, while Redo SAVR had lower paravalvular leak, severe patient-prosthesis mismatch, and postoperative gradients. Although ViV TAVR remains a feasible treatment option in high-risk patients, randomized trials are necessary to elucidate its efficacy over Redo SAVR.
Keyphrases
- aortic valve replacement
- aortic stenosis
- transcatheter aortic valve replacement
- aortic valve
- ejection fraction
- transcatheter aortic valve implantation
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- left ventricular
- coronary artery disease
- peritoneal dialysis
- patients undergoing
- prognostic factors
- type diabetes
- mitral valve
- drug induced